These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 11479476

  • 1. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W.
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [Abstract] [Full Text] [Related]

  • 2. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
    Torre-Amione G, Young JB, Durand J, Bozkurt B, Mann DL, Kobrin I, Pratt CM.
    Circulation; 2001 Feb 20; 103(7):973-80. PubMed ID: 11181472
    [Abstract] [Full Text] [Related]

  • 3. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
    Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I, VERITAS Investigators.
    Am Heart J; 2005 Jul 20; 150(1):46-53. PubMed ID: 16084150
    [Abstract] [Full Text] [Related]

  • 4. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
    Qiu CB, Qiu CS, Hess P, Clozel JP, Clozel M.
    Acta Pharmacol Sin; 2001 Jun 20; 22(6):541-8. PubMed ID: 11747762
    [Abstract] [Full Text] [Related]

  • 5. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
    Fitzgerald RK, Oishi P, Ovadia B, Ross GA, Reinhartz O, Johengen MJ, Fineman JR.
    Pediatr Crit Care Med; 2004 Nov 20; 5(6):571-7. PubMed ID: 15530195
    [Abstract] [Full Text] [Related]

  • 6. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V, Seferovic P, Dodic S, Krotin M, Neskovic A, Dickstein K, de Voogd H, Böcker C, Ziegler D, Godes M, Nakov R, Essers H, Verboom C, Hocher B.
    Circ Heart Fail; 2009 Nov 20; 2(6):523-31. PubMed ID: 19919976
    [Abstract] [Full Text] [Related]

  • 7. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
    Cotter G, Kaluski E, Stangl K, Pacher R, Richter C, Milo-Cotter O, Perchenet L, Kobrin I, Kaplan S, Rainisio M, Frey A, Neuhart E, Vered Z, Dingemanse J, Torre-Amione G.
    Eur J Heart Fail; 2004 Aug 20; 6(5):601-9. PubMed ID: 15302008
    [Abstract] [Full Text] [Related]

  • 8. Tezosentan in the treatment of acute heart failure.
    Tovar JM, Gums JG.
    Ann Pharmacother; 2003 Dec 20; 37(12):1877-83. PubMed ID: 14632537
    [Abstract] [Full Text] [Related]

  • 9. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
    McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I, VERITAS Investigators.
    JAMA; 2007 Nov 07; 298(17):2009-19. PubMed ID: 17986694
    [Abstract] [Full Text] [Related]

  • 10. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
    Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I.
    J Am Coll Cardiol; 2003 Jul 02; 42(1):140-7. PubMed ID: 12849674
    [Abstract] [Full Text] [Related]

  • 11. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
    Chin A, Radhakrishnan J, Fornell L, John E.
    J Pediatr Surg; 2001 Dec 02; 36(12):1824-8. PubMed ID: 11733915
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
    Hülsmann M, Stanek B, Frey B, Berger R, Rödler S, Siegel A, Hartter E, Schuller M, Ogris E, Pacher R.
    J Heart Lung Transplant; 1997 May 02; 16(5):556-62. PubMed ID: 9171275
    [Abstract] [Full Text] [Related]

  • 13. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
    O'Connor CM, Gattis WA, Adams KF, Shah MR, Frey A, Gheorghiade M, Randomized Intravenous Tezosentan Study Investigators.
    Am Heart J; 2003 Feb 02; 145(2 Suppl):S58-9. PubMed ID: 12594454
    [No Abstract] [Full Text] [Related]

  • 14. Tezosentan in the management of decompensated heart failure.
    Cheng JW.
    Cardiol Rev; 2005 Feb 02; 13(1):28-34. PubMed ID: 15596026
    [Abstract] [Full Text] [Related]

  • 15. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS, Gottlieb SS, Singh BN, Ramanathan KB, Ogilby JD, Ellenbogen KA.
    J Am Coll Cardiol; 1995 Dec 02; 26(7):1679-84. PubMed ID: 7594103
    [Abstract] [Full Text] [Related]

  • 16. Mixed endothelin receptor antagonism with tezosentan improves intestinal microcirculation in endotoxemic shock.
    Andersson A, Fenhammar J, Frithiof R, Weitzberg E, Sollevi A, Hjelmqvist H.
    J Surg Res; 2008 Sep 02; 149(1):138-47. PubMed ID: 18639249
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure.
    Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T.
    J Hypertens Suppl; 1994 Jul 02; 12(2):S31-5. PubMed ID: 7965263
    [Abstract] [Full Text] [Related]

  • 18. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure.
    Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C.
    Chest; 2001 Aug 02; 120(2):460-6. PubMed ID: 11502644
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.